Sutro Biopharma (STRO) EBITDA Yield: History & Chart

Sutro Biopharma, Inc.(STRO)

Biotechnology · South San Francisco, CA

$14.45-0.68 (-4.49%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

South San Francisco, CA

128 employees

www.sutrobio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jane Chung

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Sutro Biopharma, Inc. (STRO)	$139.84M	N/A	N/A	N/A	N/A
Alpha Cognition Inc (ACOG)vs ›	$139.47M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$139.04M	N/A	N/A	N/A	N/A
KORU Medical Systems, Inc. (KRMD)vs ›	$137.80M	N/A	0.23%	1.76%	3.40%
Atrium Therapeutics, Inc. (RNA)vs ›	$136.67M	N/A	N/A	N/A	N/A
Nyxoah S.A. (NYXH)vs ›	$143.10M	N/A	N/A	N/A	N/A
Organigram Global Inc. (OGI)vs ›	$136.57M	9.38%	3.05%	2.67%	2.31%
Protara Therapeutics, Inc. (TARA)vs ›	$143.60M	N/A	2.27%	2.27%	2.27%
NervGen Pharma Corp. Common stock (NGEN)vs ›	$143.84M	N/A	N/A	N/A	N/A
Freenome, Inc. (FRNM)vs ›	$133.45M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Sutro Biopharma, Inc. (STRO)

$139.84M

N/A

Alpha Cognition Inc (ACOG)vs ›

$139.47M

N/A

Immuneering Corporation (IMRX)vs ›

$139.04M

N/A

KORU Medical Systems, Inc. (KRMD)vs ›

$137.80M

N/A

0.23%

1.76%

3.40%

Atrium Therapeutics, Inc. (RNA)vs ›

$136.67M

N/A

Nyxoah S.A. (NYXH)vs ›

$143.10M

N/A

Organigram Global Inc. (OGI)vs ›

$136.57M

9.38%

3.05%

2.67%

2.31%

Protara Therapeutics, Inc. (TARA)vs ›

$143.60M

N/A

2.27%

NervGen Pharma Corp. Common stock (NGEN)vs ›

$143.84M

N/A

Freenome, Inc. (FRNM)vs ›

$133.45M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

STRO EBITDA Yield Metrics

STRO Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics